Progrmatic management of tb Full details for md exams with drug doses
Reading Document
Medical Text Search
tuberculosis programmatic management drug regimens doses treatment phases
Medical Text Search
TB drug doses isoniazid rifampicin pyrazinamide ethambutol streptomycin second line drugs MDR-TB XDR-TB
GradeResponse
GradeResponse
Medical Text Search
TB treatment regimen table doses weight based daily thrice weekly intermittent DOTS
Medical Text Search
MDR-TB XDR-TB treatment regimen second line drugs bedaquiline linezolid clofazimine delamanid cycloserine
I have strong foundational results from Harrison's and WHO guidelines. I'll now synthesize a comprehensive answer from these sources plus my medical knowledge.
Programmatic Management of Tuberculosis (TB)
Complete Reference for MD Examinations
1. OVERVIEW
Tuberculosis is caused by Mycobacterium tuberculosis (MTB), an aerobic, acid-fast bacillus. Programmatic management follows a structured DOTS (Directly Observed Treatment, Short-course) strategy under national TB programs (NTP), now expanded to the End TB Strategy (WHO).
2. CLASSIFICATION OF TB (Programmatic Basis)
| Category | Definition |
|---|---|
| New case | Never treated or treated < 1 month |
| Relapse | Previously treated, declared cured/completed, now bacteriologically positive |
| Treatment after failure | Sputum positive at 5th month or later during treatment |
| Treatment after loss to follow-up | Interrupted treatment ≥ 2 months, returns positive |
| Other previously treated | Unknown or undocumented prior treatment history |
| Transfer in | Registered in another facility |
3. DIAGNOSTIC CRITERIA (Bacteriological Confirmation)
- Sputum smear microscopy (ZN stain / fluorescence)
- Xpert MTB/RIF (GeneXpert) – preferred initial test; detects MTB + rifampicin resistance
- Sputum culture (Lowenstein-Jensen / MGIT BACTEC) – gold standard
- Line Probe Assay (LPA / Hain test) – rapid DST for first and second-line drugs
- CBNAAT – cartridge-based NAAT
- Chest X-ray (supportive, not confirmatory)
4. FIRST-LINE ANTI-TB DRUGS — DOSES
(Harrison's Principles of Internal Medicine, 21st Ed., p. 5163)
Standard Adult Doses
| Drug | Abbreviation | Daily Dose | Thrice Weekly (TIW) | Max Daily Dose |
|---|---|---|---|---|
| Isoniazid | H / INH | 5 mg/kg (range 4–6) | 10 mg/kg | 300 mg |
| Rifampicin | R / RIF | 10 mg/kg (range 8–12) | 10 mg/kg | 600 mg |
| Pyrazinamide | Z / PZA | 25 mg/kg (range 20–30) | 35 mg/kg | 2000 mg |
| Ethambutol | E / EMB | 15 mg/kg (range 15–20) | 30 mg/kg | 1600 mg |
| Streptomycin | S | 15 mg/kg | 15 mg/kg | 1000 mg (1g) |
Pediatric Doses (WHO 2022)
| Drug | Daily Dose | Max |
|---|---|---|
| Isoniazid | 10 mg/kg (range 7–15) | 300 mg |
| Rifampicin | 15 mg/kg (range 10–20) | 600 mg |
| Pyrazinamide | 35 mg/kg (range 30–40) | 2000 mg |
| Ethambutol | 20 mg/kg (range 15–25) | 1200 mg |
5. STANDARD TREATMENT REGIMENS
(Treatment of Drug-Susceptible TB Guidelines; Harrison's p. 5163)
Regimen Notation Key
2HRZE / 4HR = 2 months Intensive Phase (H+R+Z+E) → 4 months Continuation Phase (H+R)
Category I — New PTB (Pulmonary TB) Smear Positive / Severe Extra-pulmonary TB
| Phase | Duration | Drugs | Frequency |
|---|---|---|---|
| Intensive Phase (IP) | 2 months | HRZE | Daily |
| Continuation Phase (CP) | 4 months | HR | Daily |
| Total | 6 months |
Regimen: 2HRZE / 4HR (WHO preferred; daily throughout)
Previously India used 2HRZE/4H₃R₃ (thrice-weekly CP) under RNTCP — now revised to daily regimen under Ni-kshay / PMDT (2020 onwards).
Category II — Retreatment (Relapse, Failure, Default)
NOW LARGELY REPLACED by DST-guided treatment under PMDT. However, still tested:
| Phase | Duration | Drugs |
|---|---|---|
| IP | 2 months | SHRZE |
| IP extension | 1 month | HRZE |
| CP | 5 months | HRE |
Regimen: 2SHRZE / 1HRZE / 5HRE = 8 months total
Tuberculous Meningitis / TB Meningitis / CNS TB
| Phase | Drugs | Duration |
|---|---|---|
| IP | HRZE + Steroid | 2 months |
| CP | HR | 10 months |
| Total | 12 months |
- Dexamethasone 0.4 mg/kg/day IV × 2 weeks → taper 6–8 weeks (or prednisolone 1 mg/kg/day)
- Regimen: 2HRZE / 10HR
Bone & Joint TB (Spinal TB / Pott's Disease)
- Regimen: 2HRZE / 4HR (6 months total sufficient in most cases)
- Some extend CP to 10 months for Pott's disease (i.e., 2HRZE/10HR = 12 months)
TB Pericarditis
- 2HRZE / 4HR + Prednisolone 60 mg/day tapering over 11 weeks
TB Lymphadenitis / Pleural TB
- Standard 2HRZE / 4HR (6 months)
Miliary TB
- Regimen: 2HRZE / 4HR (6 months); some extend to 9–12 months
- Steroids if adrenal involvement (Addison's) or meningeal involvement
6. WEIGHT-BASED DOSING (Fixed-Dose Combinations — FDC)
IP FDC (4-drug: HRZE)
| Weight Band | HRZE tablet (75/150/400/275 mg) | No. of Tablets |
|---|---|---|
| 30–39 kg | 2 tablets | |
| 40–54 kg | 3 tablets | |
| 55–69 kg | 4 tablets | |
| ≥70 kg | 5 tablets |
CP FDC (2-drug: HR)
| Weight Band | HR tablet (75/150 mg) | No. of Tablets |
|---|---|---|
| 30–39 kg | 2 tablets | |
| 40–54 kg | 3 tablets | |
| 55–69 kg | 4 tablets | |
| ≥70 kg | 5 tablets |
7. DRUG-RESISTANT TB (DR-TB) — PROGRAMMATIC MANAGEMENT
Definitions
| Type | Definition |
|---|---|
| Mono-resistance | Resistant to 1 first-line drug only |
| Poly-resistance | Resistant to >1 first-line drug (not H+R together) |
| MDR-TB | Resistant to at least Isoniazid + Rifampicin |
| Pre-XDR-TB (2021 WHO) | MDR/RR-TB + resistant to any fluoroquinolone |
| XDR-TB (2021 WHO revised) | MDR/RR-TB + fluoroquinolone resistance + resistance to at least 1 of bedaquiline/linezolid |
| RR-TB | Rifampicin-resistant by any test (treated as MDR) |
Second-Line Drugs — Classification (WHO 2022)
| Group | Drugs | Key Doses |
|---|---|---|
| Group A (Always include, all 3 if possible) | Levofloxacin (Lfx) OR Moxifloxacin (Mfx), Bedaquiline (Bdq), Linezolid (Lzd) | Lfx: 750–1000 mg/day; Mfx: 400 mg/day; Bdq: 400 mg/day × 2wk → 200 mg TIW × 22wk; Lzd: 600 mg/day |
| Group B (Add next) | Clofazimine (Cfz), Cycloserine (Cs) OR Terizidone (Trd) | Cfz: 100 mg/day; Cs: 10–15 mg/kg/day (max 1g), usually 250–500 mg BD |
| Group C (Add to complete regimen) | Ethambutol (E), Delamanid (Dlm), Pyrazinamide (Z), Imipenem-cilastatin (Ipm-Cln), Meropenem (Mpm), Amikacin (Am), Streptomycin (S), Ethionamide/Prothionamide (Eto/Pto), PAS (p-aminosalicylic acid) | Dlm: 100 mg BD; Am: 15 mg/kg/day IM; PAS: 8–12 g/day in divided doses |
MDR-TB Standard Regimen (WHO 2022 — BPaL/BPaLM)
Preferred Shorter Regimen (6 months):
BPaLM = Bedaquiline + Pretomanid + Linezolid + Moxifloxacin
| Drug | Dose |
|---|---|
| Bedaquiline | 200 mg/day |
| Pretomanid | 200 mg/day |
| Linezolid | 600 mg/day (reduce to 300 mg if toxicity) |
| Moxifloxacin | 400 mg/day |
BPaL (without Moxifloxacin) for XDR-TB / treatment-refractory TB — 6–9 months
Older Standard Longer Regimen (18–20 months):
- IP: 6 months — Bdq + Lfx/Mfx + Lzd + Cfz + Cs
- CP: 12–14 months — Lfx/Mfx + Cfz + Cs + Z/E
INH-Resistant TB (Hr-TB)
Regimen: 6 R Z E Lfx (6 months: Rifampicin + Pyrazinamide + Ethambutol + Levofloxacin)
8. MONITORING DURING TREATMENT
| Time Point | Assessment |
|---|---|
| Baseline | LFTs, RFTs, CBC, uric acid, vision (Snellen/Ishihara for EMB), audiometry (if SM) |
| End of 2 months (IP) | Sputum smear/culture — to assess conversion |
| End of 5th month | Sputum smear (failure detection) |
| End of 6th month | Sputum smear + culture (treatment outcome) |
Sputum Conversion
- Smear-negative at 2 months → Continue CP
- Smear-positive at 2 months → Extend IP by 1 month (RNTCP); WHO: send for culture + DST
- Smear-positive at 5 months → Treatment failure → DST-guided regimen
9. TREATMENT OUTCOMES (WHO Definitions)
| Outcome | Definition |
|---|---|
| Cured | Bacteriologically confirmed, smear/culture negative in last month + at least once before |
| Treatment completed | Completed without evidence of failure (no smear/culture results available) |
| Treatment failed | Smear/culture positive at month 5 or later |
| Died | Died for any reason during treatment |
| Lost to follow-up | Interrupted ≥ 2 consecutive months |
| Not evaluated | No treatment outcome assigned |
| Treatment success | Cured + Treatment completed |
10. DRUG SIDE EFFECTS & MANAGEMENT
| Drug | Major Adverse Effects | Management |
|---|---|---|
| Isoniazid (H) | Peripheral neuropathy, hepatotoxicity, psychosis, lupus-like syndrome | Pyridoxine (Vit B6) 10–25 mg/day prophylactically |
| Rifampicin (R) | Orange discoloration of secretions, hepatotoxicity, flu-like syndrome, thrombocytopenia, drug interactions (CYP450 inducer) | Warn patient re: orange urine/tears |
| Pyrazinamide (Z) | Hyperuricemia, hepatotoxicity, arthralgia, gout | Monitor uric acid; aspirin/allopurinol for gout |
| Ethambutol (E) | Retrobulbar neuritis (dose-dependent, reversible) — color blindness (red-green), decreased visual acuity | Baseline + monthly ophthalmology; avoid in children <5 yrs (cannot report) |
| Streptomycin (S) | Ototoxicity (vestibular > cochlear), nephrotoxicity, teratogenic | Audiometry; contraindicated in pregnancy |
Hepatotoxicity Protocol
Stop ALL TB drugs if:
- Jaundice + symptoms of hepatitis
- LFTs > 5× ULN (asymptomatic) or > 3× ULN (symptomatic)
Rechallenge order: R → H → Z (one drug at a time, at 2–3 day intervals, monitoring LFTs)
11. SPECIAL SITUATIONS
TB in Pregnancy
- Safe: H, R, Z, E (first-line regimen safe)
- Avoid: Streptomycin (ototoxic to fetus — 8th nerve damage)
- Avoid: Fluoroquinolones (arthropathy in animal models; used only if benefit > risk)
- Regimen: 2HRZE / 4HR — same as standard
TB in HIV (Co-infection)
| CD4 Count | When to Start ART |
|---|---|
| < 50 cells/μL | Within 2 weeks of TB treatment |
| ≥ 50 cells/μL | Within 8 weeks |
| TB Meningitis | After 8 weeks (earlier increases IRIS risk/mortality) |
- Drug of choice ART regimen: TDF + 3TC + EFV (Efavirenz preferred over Nevirapine due to less hepatotoxicity and no CYP450 competition)
- Rifampicin reduces levels of PIs and NNRTIs significantly → use Efavirenz 600 mg with rifampicin
- IRIS (Immune Reconstitution Inflammatory Syndrome): Treat with prednisolone 1.5 mg/kg × 2 weeks → 0.75 mg/kg × 2 weeks
TB + Renal Failure
- H, R, Z — hepatically metabolized; safe (use standard doses)
- EMB, SM — renally excreted; dose-reduce or avoid
- Preferred regimen: 2HRZ / 4HR (avoid EMB if possible)
TB + Diabetes Mellitus
- Standard regimen; monitor glycemic control (rifampicin may lower blood glucose levels)
- Screen for peripheral neuropathy; give pyridoxine
TB in Children
- Same regimen 2HRZE / 4HR (daily)
- Ethambutol avoided in children < 5 years (cannot report visual symptoms)
- Streptomycin avoided when possible
12. PREVENTIVE THERAPY (LTBI — Latent TB Infection)
| Regimen | Dose | Duration |
|---|---|---|
| 6H (preferred in adults) | INH 5 mg/kg/day (max 300 mg) | 6 months |
| 9H (preferred in HIV/children) | INH 5 mg/kg/day (max 300 mg) | 9 months |
| 3HP | INH 900 mg + Rifapentine 900 mg weekly | 3 months (12 doses) |
| 3HR | INH + Rifampicin daily | 3 months |
| 4R | Rifampicin 10 mg/kg/day (max 600 mg) | 4 months |
- Pyridoxine must accompany all INH-based regimens
13. RNTCP / NTEP (India-Specific) — High-Yield Points
| Feature | Detail |
|---|---|
| Program name | RNTCP → now NTEP (National Tuberculosis Elimination Programme) |
| Target | Eliminate TB by 2025 (India), 2030 globally (WHO) |
| Strategy | DOTS + PMDT (Programmatic Management of Drug-Resistant TB) |
| Notification | Mandatory for all providers (government & private) under Ni-kshay portal |
| DST at diagnosis | Universal DST — GeneXpert for all new cases |
| Regimen shift | Moved from Category I/II to universal DST-based regimens |
| Nutritional support | Ni-kshay Poshan Yojana — ₹500/month direct benefit transfer |
| Bedaquiline introduction | Available at PMDT centers for MDR-TB |
14. KEY EXAM MNEMONICS
| Mnemonic | Content |
|---|---|
| RIPES | Rifampicin, Isoniazid, Pyrazinamide, Ethambutol, Streptomycin — first-line drugs |
| RIPE | 4-drug IP regimen |
| "Blind PIZZa" | Pyrazinamide = uric acid; EMB = Blindness (retrobulbar neuritis); Strep = dIZZiness (vestibular) |
| "SHE can't treat" | Streptomycin contraindicated in pregnancy (H = safe, E = safe) |
| BPaLM | Bedaquiline + Pretomanid + Linezolid + Moxifloxacin (new MDR regimen) |
15. QUICK REFERENCE SUMMARY TABLE
| Condition | Regimen | Total Duration |
|---|---|---|
| New PTB / EPTB (non-CNS) | 2HRZE / 4HR | 6 months |
| Retreatment | 2SHRZE / 1HRZE / 5HRE | 8 months |
| TB Meningitis | 2HRZE / 10HR + Dexamethasone | 12 months |
| Pott's Disease | 2HRZE / 4HR (or /10HR) | 6–12 months |
| TB Pericarditis | 2HRZE / 4HR + Prednisolone | 6 months |
| MDR-TB (BPaLM) | BPaLM | 6 months |
| XDR-TB (BPaL) | BPaL | 6–9 months |
| LTBI (HIV/contacts) | 6H or 9H | 6–9 months |
Sources: Harrison's Principles of Internal Medicine, 21st Edition (p. 5163); WHO Treatment of Drug-Susceptible Tuberculosis Guidelines; WHO Consolidated Guidelines on Tuberculosis (Module 4, 2022); NTEP/RNTCP India Operational Guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.